(2R)-2-[(叔丁氧基羰基)氨基]-3-(2,5-二氟苯基)丙酸 | 261380-31-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2R)-2-[(叔丁氧基羰基)氨基]-3-(2,5-二氟苯基)丙酸
• 中文别名: BOC-D-2,5-二氟苯丙氨酸
• 英文名称: (R)-N-(1,1-dimethylethoxycarbonyl)-2,5-difluorophenylalanine
• 英文别名: (R)-2-tert-butoxycarbonylamino-3-(2,5-difluoro-phenyl)-propionic acid；Boc-2,5-difluoro-D-phenylalanine；(2R)-3-(2,5-difluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 261380-31-8
• 化学式: C₁₄H₁₇F₂NO₄
• 分子量: 301.29
• InChiKey: DYSZJZJRRBKIDS-LLVKDONJSA-N

物化性质

• 沸点：
  424.5±45.0 °C(Predicted)
• 密度：
  1.270±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (2R)-2-[(叔丁氧基羰基)氨基]-3-(2,5-二氟苯基)丙酸 在 三乙胺 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 生成 (R)-3-[(1,1-dimethylethoxycarbonyl)amino]-1-diazo-4-(2,5-difluorophenyl)butan-2-one
  参考文献：
  名称：

  发现有效的和选择性的基于β-高苯丙氨酸的二肽基肽酶IV抑制剂。

  摘要：

  内部筛选铅β-氨基酰基脯氨酸8的修饰得到了等价的噻唑烷化物9。对9的苯环的广泛SAR研究导致发现了一系列新的有效的和选择性的DP-IV抑制剂。事实证明，在2位上引入氟对于该系列的效能至关重要。2,5-二氟（22q）和2,4,5-三氟（22t）类似物是DP-IV的有效抑制剂（分别为IC（50）= 270、119nM）。

  DOI：

  10.1016/j.bmcl.2004.06.099
• 作为产物：
  描述：

  2,5-二氟苄溴 在 盐酸 、 lithium hydroxide 、 正丁基锂 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 41.83h， 生成 (2R)-2-[(叔丁氧基羰基)氨基]-3-(2,5-二氟苯基)丙酸
  参考文献：
  名称：

  (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

  摘要：

  A novel series of beta-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC(50) = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of compound 1, was selected for development as a potential new treatment for type 2 diabetes.

  DOI：

  10.1021/jm0493156

文献信息

• BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150359793A1

  公开（公告）日：2015-12-17

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，该化合物在治疗或预防二肽基肽酶-IV酶参与的疾病中具有用途，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• [EN] 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] DERIVES DE 3-AMINO-4-PHENYLBUTANOIQUE ACIDE UTILISES EN TANT QU'INHIBITEURS DE DIPEPTIDYL PEPTIDASE POUR LE TRAITEMENT OU LA PREVENTION DU DIABETE
  申请人：MERCK & CO INC

  公开号：WO2004058266A1

  公开（公告）日：2004-07-15

  The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及3-氨基-4-苯基丁酸衍生物，这些衍生物是二肽基肽酶-IV酶（'DP-IV抑制剂'）的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• Benzazepinone Nav1.7 blockers: Potential treatments for neuropathic pain
  作者：Scott B. Hoyt、Clare London、Hyun Ok、Edward Gonzalez、Joseph L. Duffy、Catherine Abbadie、Brian Dean、John P. Felix、Maria L. Garcia、Nina Jochnowitz、Bindhu V. Karanam、Xiaohua Li、Kathryn A. Lyons、Erin McGowan、D. Euan MacIntyre、William J. Martin、Birgit T. Priest、McHardy M. Smith、Richard Tschirret-Guth、Vivien A. Warren、Brande S. Williams、Gregory J. Kaczorowski、William H. Parsons

  DOI：10.1016/j.bmcl.2007.09.032

  日期：2007.11

  A series of benzazepinones were synthesized and evaluated as hNa(v)1.7 sodium channel blockers. Several compounds from this series displayed good oral bioavailability and exposure and were efficacious in a rat model of neuropathic pain.

  合成了一系列苯并ze庚酮，并将其评估为hNa（v）1.7钠通道阻滞剂。该系列中的几种化合物具有良好的口服生物利用度和暴露能力，并且在神经性疼痛的大鼠模型中有效。
• Development of a Practical Synthesis of DPP IV Inhibitor LY2497282
  作者：Hannah Yu、Rachel N. Richey、James R. Stout、Mark A. LaPack、Ruilin Gu、Vien V. Khau、Scott A. Frank、Joel P. Ott、Richard D. Miller、Michael A. Carr、Tony Y. Zhang

  DOI：10.1021/op700235c

  日期：2008.3.1

  for the preparation of multikilogram quantities is described. The key step involved a stereoselective addition of the dianion of nicotinamide 8 to N-dibenzyl-protected α-amino aldehyde 12, which was derived from N-acetyl-protected amino ester 14 without epimerization. The desired Felkin-Anh nonchelation controlled anti-amino alcohol 11 was isolated with >99% HPLC area and >99% ee by crystallization

  描述了一种新的合成途径，可以合成LY2497282（1），这是一种潜在的，选择性的DPP IV抑制剂，适用于潜在的糖尿病治疗，适用于多千克量的制备。关键步骤涉及将烟酰胺8的二价阴离子立体选择性地添加 到 N-二苄基保护的α-氨基醛12中，该α-氨基醛 12衍生自 N-乙酰基保护的氨基酯 14而没有差向异构化。通过结晶分离具有＞ 99％HPLC面积和＞ 99％ee的期望的Felkin-Anh非螯合控制的 抗氨基醇 11。在转移氢化条件下除去二苄基保护基后，LY2497282（1）从N-乙酰基保护的氨基酯 14开始，以六步最长的线性序列最终以39％的总收率获得 。
• Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  申请人：——

  公开号：US20040167133A1

  公开（公告）日：2004-08-26

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，该化合物对于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病非常有用。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物预防或治疗二肽基肽酶-IV酶参与的疾病的方法。